Helus Pharma reports positive Phase 3 depression-trial results as shares fall

On November 16, Helus Pharma reported topline results from the Phase 3 APPROACH study of HLP003 as an adjunctive treatment for major depressive disorder. The trial met its primary endpoint, with a 7.6-point placebo-adjusted improvement on the MADRS at Week 6 and a statistically significant effect at Day 2; three treatment-related serious adverse events were also reported. Helus Pharma's same-day Q2 results showed a GAAP loss per share of -$1.41, missing estimates by $0.68, while the company expects topline EMBRACE results in the fourth quarter of 2027.

The APPROACH results provide a positive late-stage efficacy readout, but HLP003 remains under clinical development and the next reported milestone is expected in the fourth quarter of 2027. The simultaneous earnings miss and disclosed serious adverse events coincided with a sharp decline in Helus Pharma shares.

  • 1The APPROACH trial enrolled 222 participants with moderate to severe major depressive disorder.
  • 2HLP003 produced a 7.6-point placebo-adjusted MADRS improvement at Week 6, with a p-value of less than 0.0001.
  • 3A statistically significant treatment effect was observed at Day 2, with a 5.0-point placebo-adjusted MADRS reduction and p=0.0013.
  • 4Three treatment-related serious adverse events occurred among participants receiving HLP003.
  • 5Helus Pharma reported a GAAP loss per share of -$1.41, which missed analyst estimates by $0.68.
  • 6The company expects topline EMBRACE results during the fourth quarter of 2027.
  • Reported share declines differ across materials, ranging from 8.86% to 25.4%, likely reflecting different measurement times or trading sessions.
  • Material 6 uniquely attributes a $79 price-target increase to Lucid Capital and reports maintained positive ratings from Jefferies and Barclays; those claims are not detailed in the available material body.

Sources